Trends of minimally invasive surgery in the primary treatment of cervical cancer
Author:
- 29 October 2024
- journal article
- research article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (S1) , 72-78
Abstract
Minimally invasive surgery (MIS), including laparoscopic and robot‐assisted procedures, has rapidly advanced in the treatment of gynecologic malignancies worldwide. However, its adoption and insurance coverage in AOFOG countries remain limited, particularly for advanced uterine and ovarian cancers. This limitation poses a challenge to the widespread use of MIS, highlighting the need for a more comprehensive evaluation of its role and the skills required by gynecologic oncologists to ensure safe and effective treatment. Furthermore, the Laparoscopic Approach to Cervical Cancer trial significantly impacted perceptions of MIS, revealing higher recurrence rates and inferior overall survival for minimally invasive radical hysterectomy (MIS‐RH) compared to abdominal radical hysterectomy. Subsequent studies confirmed these findings, raising questions about the suitability of MIS‐RH, particularly in centers with limited experience. Key issues affecting MIS outcomes include surgical expertise and tumor spillage prevention. As the landscape of cervical cancer treatment evolves, the integration of radiotherapy, chemotherapy, and immune therapies has challenged the traditional reliance on surgical monotherapy. There also exists ongoing debate over the optimal use of MIS in primary treatment and salvage surgery for cervical cancer to refine MIS techniques and explore their role in preserving fertility and managing residual disease post‐chemoradiotherapy. For ensuring MIS as a viable treatment option, it is continuously necessary accumulating real‐world data and reassessing surgical strategies to balance efficacy, safety, and patient preferences.Keywords
This publication has 25 references indexed in Scilit:
- Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialThe Lancet, 2024
- Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021International Journal of Clinical Oncology, 2024
- Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic reviewGynecologic Oncology, 2022
- Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081Gynecologic Oncology, 2022
- Radical Hysterectomy for Cervical Cancer: the Right Surgical ApproachCurrent Treatment Options in Oncology, 2022
- Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage: a retrospective cohort study using a nationwide registry database in JapanGastric Cancer, 2021
- Minimally invasive surgery vs laparotomy for early stage cervical cancer: A propensity score‐matched cohort studyCancer Medicine, 2020
- Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomesGynecologic Oncology, 2020
- Comparison of adjuvant therapy for node‐positive clinical stage IB‐IIB cervical cancer: Systemic chemotherapy versus pelvic irradiationInternational Journal of Cancer, 2017
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997